Synactix Orphan Drug Filing: New therapy for metastatic medullary thyroid carcinoma (MTC)

by Samantha Whitman, Ph.D.

MTC is a rare, incurable disease. Synactix is dedicated to creating safer, more effective treatment options to patients in need.
Tucson, AZ United States Rare Diseases

All Team Company Patients Physicians Hospital Partners Innovation Details Supporters Comments Updates

About our project

The problem we solve: Metastatic Medullary Thyroid Carcinoma (MTC) is an incurable disease with poor prognosis and frequent de novo resistance to current treatment options. MTC effects nearly 2,000 new patients each year in the US and almost 9,000 globally. Current treatment options produce only partial and often temporary responses. Further, these treatments are plagued with adverse side-effects that frequently evolve into dose-limiting toxicities and treatment rejection. Synactix's goal for treating this rare cancer is to provide patients with a safer, more effective cancer treatment to extend overall survival and improve quality of life.

About our solution: Synactix is derived from synergy and action. Synactix is founded on the principle that the 'one-drug, one-target' approach is inadequate to treat many types of human disease. We have established a robust targeted strategy focused on single-agent polypharmacology, or ‘one-drug, many targets’. Single-agent targeting of multiple pathways in human disease is the future of modern medicine. MTC is frequently (>50%) driven by a specific oncogene (cancer gene) known as RET. Tumors also grow and spread by recruiting new blood vessels through a pathway controlled by another gene, VEGFR2. We have designed a single small molecule that inhibits both RET and VEGFR2 at the same therapeutic dose, effectively blocking the cancer driving oncogene while simultaneously suppressing the tumor’s blood supply.

Progress to date:Synactix is in preclinical stages of development of our lead compound for metastatic medullary thyroid carcinoma. We have generated robust efficacy and safety data in animal models (mouse, rat, and dog) that support further clinical development of our lead candidate, Pz-1. The figure below shows how even small doses of Pz-1 are effective at reducing tumor volumes in mice. Synactix has been awarded a Phase 1 STTR small business grant from the National Caner Institute (NCI) to pursue commercial development of Pz-1.

About Our Team

Creator: Samantha Whitman

Location: Arizona

Bio: Samantha got her PhD in 2011 in Cell & Molecular biology and has been working on entrepreneurial endeavors in cancer drugs and diagnostics ever since! With start-up experience in companies from 2 to 70 people, she happily wears many hats dedicated to acceleration of cancer technology innovations to improve patient care.

Title: VP R&D

Advanced Degree(s): Ph.D.

LinkedIn: https://www.linkedin.com/in/samantha-whitman-9527402

About Team Members

Brendan Frett
Co-Founder, CEO, PhD
Biography: Brendan has strong expertise in drug synthesis and therapeutic development. He is highly skilled at identifying new drug targets and producing next-generation agents that can modulate target activity. Previous work completed by Dr. Frett has led to the generation of two biotechnology companies and numerous authored and co-authored publications.
Title: Co-Founder, CEO
Advanced Degree(s): PhD
LinkedIn: https://www.linkedin.com/in/brendan-frett-ph-d-7868bb99

Hongyu Li
Co-Founder, PhD
Biography: Dr. Hong-yu Li has extensive experience in drug discovery and development, with a particular focus on oncology. Dr. Li has 10+ years of experience at Eli Lilly & Co. as a senior organic chemist, research scientist and senior research scientist. Before leaving Lilly, he was a principle research scientist and team leader.
Title: Co-Founder
Advanced Degree(s): PhD
LinkedIn: https://www.linkedin.com/in/hong-yu-li-24a6372b

Thomas Goodman
Business Development manager, PhD
Biography: Tom is a program administrator with background in university technology transfer, licensing, and new venture creation. He has worked for over 20 years at the interface of technology and business as a former Director for Research Corporation Technologies, Inc. and VP of Business Development at Arizona Science and Technology Enterprises, LLC.
Title: Business Development manager
Advanced Degree(s): PhD
LinkedIn: https://www.linkedin.com/in/thomascgoodman

About Our Company

Synactix Pharmaceuticals

Location: 9040 S Rita Rd
1270
Tucson, AZ 85747

Founded: 2014

Website: http://www.synactixpharma.com

Twitter: @SynactixPharma

Facebook: https://www.facebook.com/synactixpharma

Other link: https://www.linkedin.com/company/synactix-pharmaceuticals-inc-

Product Stage: Prototype/MVP

YTD Sales: Working on it

Employees: 3-5

How We Help Patients

Today, metastatic medullary thyroid carcinoma (MTC) is an incurable disease with poor prognosis and frequent genetic resistance to current treatment options. As a patient or patient’s loved one, you already know that MTC can be difficult to treat. Tumors do not respond to radio-iodine and a more personalized treatment option is necessary to extend overall survival and improve quality of life. Synactix wants to help patients by designing smarter, safer drugs. Our strategy is to target two cancer pathways with one drug to disrupt both the “driving” and “supporting” tumor biology at one therapeutic dose. Today’s drugs for MTC have major activity on the "supporting" pathway and attempting to target the driving pathway in MTC causes dose limiting toxicity and limits the patients’ tolerance for the drug. The Synactix strategy of 'one-drug, multiple targets' may eliminate potential for drug-drug interactions and improves the safety and tolerability of the cancer medication.

How We Help Physicians

As a healthcare provider, you know that MTC is an incurable disease with poor prognosis and frequent de novo resistance to current treatment options. You may have seen some of your own patients develop resistance to current therapies or patients that have to stop treatment due to significant side-effects and adverse events. Single agent polypharmacology (targeting multiple pathways with one molecule) is an innovative approach in oncology, with the potential for lasting and robust efficacy. Synactix Pharmaceuticals has designed a single small molecule (called Pz-1) that simultaneously inhibits the pro-survival activity of all known RET (rearranged during transfection) mutations and the angiogenic activity of VEGFR2 (vascular endothelial growth factor receptor) at very low doses (IC50s ? 1.0 nM). Our preclinical data show that Pz-1 can attenuate tumor growth in TT cell xenograft models at a dose of only 0.3 mg/kg (unpublished data). To achieve similar efficacy in this same model, Cabozantinib required 30 mg/kg (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868259/) and Vandetanib required 50 mg/kg (see supplement:http://erc.endocrinology-journals.org/content/18/1/1.full.pdf). Further, non-GLP animal studies show high oral availability and large potential therapeutic window, as adverse effects are not evident below doses of 100 mg/kg (single dose), 30 mg/kg (repeat dosing) and 150 mg/kg (single dose) in each model, respectively. As Physicians and health care providers, we are seeking your help to further the development of this promising therapeutic. There are many ways to contribute, share your professional experience, a research collaboration, helping with Clinical trial design and execution, or financially. Please reach out to us if you are interested in Synactix, Pz-1 and the potential for a new therapy for your patients.

How We Help Hospitals

Synactix is dedicated to improving patient care and building safer medications. This will hopefully equate to fewer side effects and adverse events, which means hospital costs and unnecessary visits go down. In addition, we are focused on creating orally-available medications, reducing the need for patient hospital visits for daily treatments. This will help to free up your valuable resources to expand care options in other critical areas. We are all working to improve patient and health care, join us in building next-generation cancer therapeutics to advance this goal.

How We Help Partners

Synactix is building an innovative solution to rare RET driven cancers. While MTC is the most effected by RET as a tumor driver, several others including Lung, Leukemia and papillary thyroid cancers also have RET as the driving biological pathway of cancer. The Synactix strategy will provide robust clinical candidates that may be eligible for Orphan and Breakthrough status. Further, due to the specificity of our lead candidate, Pz-1, against RET driven cancers, biomarkers and companion diagnostics are part of the Synactix clinical development strategy moving forward. Synactix delivers to potential partners a robust, safe, targeted therapy with several developmental and regulatory advantages to streamline progress into the clinic and eventual market approval.

Innovation Details

Intellectual Property Summary

A world-wide PCT (Patent Cooperation Treaty) filing was made with a 2014-06-03 priority date. This patent (WO2015187818A1) entitled Benzimidazole analogues and related methods covers the composition of matter of our lead drug candidate, Pz-1 and builds a

Patent Link
https://www.google.com/patents/WO2015187818A1?cl=en&dq=WO+2015187818+A1

Clinical Information

Synactix has developed a strong pre-clinical drug candidate for MTC and we are working doggedly towards our first-in-human clinical trial! To date, we have established very strong efficacy data in multiple animal models of MTC. Our candidate Pz-1 shows potent efficacy on clinically relevant tumor models at <100x the dose of currently FDA approved therapies. Some technical details are published here in Angewandte Chemie: http://onlinelibrary.wiley.com/doi/10.1002/anie.201501104/full. Importantly, our drug has been specifically designed to both the tumor driver and the supporting cast responsible for bringing in blood supply. This is a new paradigm in personalized medicine, but the main purpose is to deliver safer, smarter drugs. We will need to engage with the FDA and proceed through normal drug development channels with clinical trials. However, our intent for designing one-drug that targets multiple disease pathways is to deliver on the FDA's requirement for safer therapies.

Regulatory Status

Synactix is in pre-clinical stages of development. We are starting our Investigational New Drug (IND)-enabling studies in July and are targeting our first contact with FDA (in pre-IND meeting) in ~March of 2017. Synactix is engaging with INC Research to assist in regulatory and clinical study design and execution. Synactix has applied for national and international grants to support our Phase I clinical trials, which we aim to begin in August of 2017.

How we will use the funds raised

The primary goal of this fundraising campaign is to raise the necessary funds to support preparation and submission of an Orphan Drug Application (ODA) for Pz-1 in metastatic medullary thyroid carcinoma. Synactix requires regulatory and domain expertise to help assemble and submit this application. A successful ODA is a key milestone for Synactix and can help lower the costs of development in clinical trials. If Synactix is fortunate enough to exceed our goal, additional funding raised from this campaign will go first towards preparation of our IND filing with the FDA, then the design and execution of a pivotal Phase 1 (first in human) clinical trial. Contributions will NOT be used to fund any salaries, but will be directly involved in advancing our candidate drug towards the clinic to provide patients with a safer, more effective treatment option for their cancer.

Thank You

From our team at Synactix, we want to say thank you for your interest and hopefully, your support of this campaign. Hongyu and Brendan have been working towards a new paradigm in personalized medicine for several years because the current theme of 'one-drug, one-target' is not good enough for patient care. We believe that smarter, safer drugs for cancer therapy can be built and medicine should not make a person worse, but better. With your help we can change the landscape of cancer therapy and a

Supporters

Comments

    No comments found .

Login to post your comment!
Click here to Login

Updates

  • September is Thyroid Cancer Awareness Month!
    Thanks to everyone who has visited, liked, followed and pledged to our campaign! We're >10%, getting close but still have some ground to cover. Please consider our project a tax deductible way of helping to spread awareness for thyroid cancer and pass the link on to your friends, family and co-workers. Thanks , The Synactix Team

$ 225

pledged of $ 5,000 goal

  • This campaign has ended but you can still get involved.
    See options below.

17

Interest
Score

0

Adoption
Score


Rewards All contributions are tax-deductible.